GIAPREZA is the first and only FDA-approved synthetic human angiotensin II that increases blood pressure in adults with septic or other distributive shock.

Abbreviations: MAP, mean arterial pressure; RAAS, renin-angiotensin-aldosterone system.

aTarget MAP defined as ≥75 mmHg or an increase from baseline of ≥10 mmHg without an increase in baseline vasopressor therapy.

bGIAPREZA and placebo were studied in conjunction with norepinephrine, epinephrine, dopamine, phenylephrine, and vasopressin.

cResults from the ATHOS-3 trial.

dResponse was defined as achievement of target MAP ≥75 mmHg or increase of ≥10 mmHg from baseline without an increase in baseline vasopressor therapy.